Ipsen invests $45 million in US R&D facility

French drugmaker Ipsen (Euronext: IPN) says its USA-based subsidiary, Biomeasure and its North American Operations group will further expand its commitment, investment and commercial presence in the US market. Ipsen will make a multi-million dollar capital investment in its Milford, Massachusetts, R&D and technical operations facility, and will relocate US Operations headquarters from Brisbane, California, to Bridgewater, New Jersey, in order to enhance the North American commercial organization.

“Ipsen’s Milford-based facility is at the cutting edge of innovative, impactful and high-performing research, development and manufacturing capabilities focused on delivering new treatments for serious and life-threatening diseases to patients,” said Cynthia Sylvestre, president, Biomeasure, and vice president, Milford site head, adding: “We are confident that investing $45 million in this unique site, in such close proximity to the impressive concentration of scientific skills and talent in Massachusetts, will enable Ipsen to expand its bio-therapeutic technological platforms and pipeline.”

The existing 77,000 square-foot Milford facility serves as a center for Ipsen’s US-based peptide and toxin R&D platforms, as well as a cGMP manufacturing facility focused on production of recombinant proteins for the treatment of hemophilia.